TW202432587A - 產生雙特異性蛋白之方法 - Google Patents

產生雙特異性蛋白之方法 Download PDF

Info

Publication number
TW202432587A
TW202432587A TW112150225A TW112150225A TW202432587A TW 202432587 A TW202432587 A TW 202432587A TW 112150225 A TW112150225 A TW 112150225A TW 112150225 A TW112150225 A TW 112150225A TW 202432587 A TW202432587 A TW 202432587A
Authority
TW
Taiwan
Prior art keywords
protein
antibody
heterodimeric
domain
igg
Prior art date
Application number
TW112150225A
Other languages
English (en)
Chinese (zh)
Inventor
克魯伊夫 科內利斯 阿德里安 德
法蘭西斯卡 莫騰森
Original Assignee
荷蘭商美勒斯公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 荷蘭商美勒斯公司 filed Critical 荷蘭商美勒斯公司
Publication of TW202432587A publication Critical patent/TW202432587A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TW112150225A 2022-12-27 2023-12-22 產生雙特異性蛋白之方法 TW202432587A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL2033843 2022-12-27
NL2033843 2022-12-27

Publications (1)

Publication Number Publication Date
TW202432587A true TW202432587A (zh) 2024-08-16

Family

ID=85158672

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112150225A TW202432587A (zh) 2022-12-27 2023-12-22 產生雙特異性蛋白之方法

Country Status (9)

Country Link
US (1) US20260209390A1 (cg-RX-API-DMAC7.html)
EP (1) EP4642811A1 (cg-RX-API-DMAC7.html)
JP (1) JP2026500710A (cg-RX-API-DMAC7.html)
KR (1) KR20250129720A (cg-RX-API-DMAC7.html)
CN (2) CN121824747A (cg-RX-API-DMAC7.html)
AU (1) AU2023418349A1 (cg-RX-API-DMAC7.html)
IL (1) IL321671A (cg-RX-API-DMAC7.html)
TW (1) TW202432587A (cg-RX-API-DMAC7.html)
WO (1) WO2024144396A1 (cg-RX-API-DMAC7.html)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801687A (en) 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
US5151504A (en) 1989-11-17 1992-09-29 E. R. Squibb & Sons, Inc. Method for purification of monoclonal antibodies
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
IN2014CN03887A (cg-RX-API-DMAC7.html) * 2011-10-27 2015-10-16 Genmab As
CA3094318A1 (en) 2018-03-30 2019-10-03 Merus N.V. Multivalent antibody
EP3966238A2 (en) 2019-05-09 2022-03-16 Merus N.V. Variant domains for multimerizing proteins and separation thereof
CN116462766A (zh) 2020-05-21 2023-07-21 美勒斯公司 用于生产ig样分子的方法和手段

Also Published As

Publication number Publication date
KR20250129720A (ko) 2025-08-29
JP2026500710A (ja) 2026-01-08
AU2023418349A1 (en) 2025-07-03
WO2024144396A1 (en) 2024-07-04
US20260209390A1 (en) 2026-07-23
IL321671A (en) 2025-08-01
EP4642811A1 (en) 2025-11-05
CN121824747A (zh) 2026-04-10
CN120641444A (zh) 2025-09-12

Similar Documents

Publication Publication Date Title
TWI359027B (en) Bivalent, bispecific antibodies
CN110256569B (zh) 具有交换结合区取向的双重可变区抗体样结合蛋白
JP5681482B2 (ja) 二重特異性抗体およびその作製方法
EP3041862B1 (en) Constant chain modified bispecific, penta- and hexavalent ig-m antibodies
JP2019528051A (ja) 修飾抗原結合Ｆａｂ断片及びこれを含む抗原結合分子
TW200932271A (en) Bivalent, bispecific antibodies
RS62509B1 (sr) Bispecifična anti-vegf/anti-ang-2 antitela i njihova upotreba u lečenju očnih vaskularnih bolesti
CN114786730A (zh) N-端scFv多特异性结合分子
CN110382537B (zh) 抗体结构域的优选配对
US20230167200A1 (en) Platform for constructing multispecific antibody
WO2017096361A1 (en) Disulfide-stabilized fabs
TWI918721B (zh) Egfr結合複合物及其製備和使用方法
KR20220017909A (ko) 단백질 다량체화를 위한 변이체 도메인 및 그의 분리
TWI870360B (zh) 雙特異性抗體構建體之下游加工
KR20250051674A (ko) 다중특이적 항체의 중쇄 및 경쇄의 상동성 페어링을 촉진하는 돌연변이체
TW202506725A (zh) 三特異性工程化抗體
JP2026500710A (ja) 二重特異性タンパク質を製造する方法
JP2023516380A (ja) プロテアーゼプロセシングした分子
US20240417467A1 (en) Bispecific Engineered Antibodies
US20250011426A1 (en) Engineered Antibodies
WO2025162458A1 (zh) 融合抗体及其制备和应用
RU2820254C2 (ru) Мультиспецифические связывающие белки на основе псевдо-fab
Rivera-Castro et al. Comparative analysis of manufacturability and binding of various bispecific antibody architectures
RU2810748C2 (ru) Усовершенствованные прокоагулянтные антитела
WO2025137454A1 (en) Stabilizing homodimer mutations for two cell heterodimer production